NCIt definition : An orally available inhibitor of specific mutant forms of the mitochondrial enzyme
isocitrate dehydrogenase type 2 (IDH2), with potential antineoplastic activity. Upon
administration, enasidenib specifically inhibits various mutant forms of IDH2, including
the IDH2 variants R140Q, R172S, and R172K, which inhibits the formation of 2-hydroxyglutarate
(2HG). This may lead to both an induction of cellular differentiation and an inhibition
of cellular proliferation in IDH2-expressing tumor cells. IDH2, an enzyme in the citric
acid cycle, is mutated in a variety of cancers; it initiates and drives cancer growth
by blocking differentiation and the production of the oncometabolite 2HG.;
UNII : 3T1SS4E7AG;
InChIKey : DYLUUSLLRIQKOE-UHFFFAOYSA-N;
CAS number : 1446502-11-9; a href https://gsrs.ncats.nih.gov/ginas/app/beta/browse-substance?search 1446502-11-9
alt lien vers site G-SRS target _blank img src /img/logos/logo_g-srs.png alt Logo
G-SRS /a ;